The Capital Markets team advised joint book-running managers Jefferies LLC and Goldman Sachs & Co. LLC, and book-running manager, Cantor Fitzgerald & Co., for Taysha Gene Therapies’ (Nasdaq: TSHA) underwritten public offering of 14,361,113 shares of its common stock at a public offering price of $2.25 per share and in lieu of common stock to certain investors, pre-funded warrants to purchase up to 18,972,221 shares of common stock at a public offering price of $2.249 per pre-funded warrant. Taysha also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $75 million.
Taysha is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.
The Goodwin team was led by Ben Marsh, Janet Hsueh, Kristen Kennedy, and Haylee Brown and included Steven Tjoe and Sukrti Thonse (FDA); Heath Ingram (Healthcare); Olivia Uitto and Sabrina Poulos (IP); Alex Intile (Cyber); Jason Wilcox and Gozde Guckaya (OFAC); Willam Stern and Ximeng (Sammy) Tang (AML); Dan Karelitz (Tax); and Mark Burnett (Opinions), with invaluable assistance from Justin Platt.